Drug repurposing in pharmaceutical industry and its impact on market access: market access implications

Journal of Market Access and Health Policy

Volumn 2, Issue 1, 2014, Pages

  Murteira, Susana ^a,b   Millier, Aurélie ^c   Toumi, Mondher ^a  

^a UNIVERSITÉ LYON 1   (France)

^b Lundbeck   (France)

^c CREATIV CEUTICAL   (France)

Author keywords

market access; price; reformulation; reimbursement; repositioning; repurposing

Indexed keywords

EID: 85164333266     PISSN: None     EISSN: 20016689     Source Type: Journal    
DOI: 10.3402/jmahp.v2.22814     Document Type: Article

References (14)

1. MurteiraS, GhezaielZ, KarrayS, LamureM.Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: Reassessment of nomenclature. JMAHP. 2013; 1: 1.
2. SmithRB.Repositioned drugs: Integrating intellectual property and regulatory strategies. 2011; 8(3–4):131–7. Drug Discov Today Ther Strateg.
3. Murteira S, Millier A, Ghezaiel Z, Lamure M. Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: Regulatory implications. JMAHP. 2014; 2: 22813. doi: http://dx.doi.org/10.3402/jmahp.v2.22813.
4. Kanavos P, Schurer W, Vogler S. Europa. European Commission [updated March 2011]. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/structimpact_pharmaprices_032011_en.pdf [cited 3 March 2013].
5. WHO Collaborating Centre for Drug Statistics Methodology. Definition and general considerations. World Health Organization-International language for drug utilization research ATC/DDD [updated 17 December 2009]. Available from: http://www.whocc.no/ddd/definition_and_general_considera/ [cited 5 March 2013].
6. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Rev. 2010. Available from: http://apps.who.int/classifications/icd10/browse/2010/en [cited 3 December 2012].
7. World Health Organization. Prevalence (000s) for selected causes, in WHO Regions (a), estimates for 2004. WHO Health Statistics. 2004. Available from: http://www.who.int/healthinfo/global_burden_disease/en/ [cited 5 November 2012].
8. World Health Organization. GLOBOCAN 2008 Project. International Agency for Research on Cancer- ONLINE ANALYSIS>PREVALENCE. Available from: http://globocan.iarc.fr/ [cited 25 November 2012].
9. Decision Resources.Patient Base. Decision Resources L.L.C. 2009. Available from: https://biopharma.decisionresourcesgroup.com/Disease/Browse?filterBy=Therapy+Area [cited 30 January 2012].
10. Centers for Disease Control and Prevention. Data & Statistics. Centers for Disease Control and Prevention [updated 11 January 2011]. Available from: http://www.cdc.gov/ [cited 14 April 2012].
11. World Health Organization. Regional burden of disease estimates for 2004. WHO Health Statistics–Standard DALYs (3% discounting, age weights). 2011. Available from: http://www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html [cited 23 May 2012].
12. World Health Organization. Quantifying environmental health impacts. WHO Global Burden of Disease–Global Burden of Disease Concept. 2006. Available from: http://www.who.int/quantifying_ehimpacts/publications/en/9241546204chap3.pdf [cited 21 February 2013].
13. Micromedex. MICROMEDEX® 2.0 and MICROMEDEX® 1.0 (Healthcare Series); 2007, 2009. Available from: http://www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/CS/768528/ND_PR/evidencexpert/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/CCBDDD/ND_PG/evidencexpert/ND_B/evidencexp [cited 11 September 2011].
14. Datamonitor Reports.Drug repositioning strategies: Serendipity by design. 2008; New York: Datamonitor.DMHC2400.